CDK4/6 inhibitors in breast cancer: spotting the difference

A phase 3 study with dalpiciclib reinforces the efficacy of CDK4/6 inhibitors in select patients with metastatic breast cancer; with several such inhibitors available, more evidence is needed to help guide treatment decisions.

Automated summary

The phase 3 study with dalpiciclib demonstrates the efficacy of CDK4/6 inhibitors in certain patients with metastatic breast cancer, providing valuable evidence for treatment decisions in the presence of multiple available inhibitors.